Verdict · the IC editorial
What we actually think
App-chain optimised for derivatives/order-book trading with a unique value-capture burn. Niche by design.
Full editorial verdict pending — second-paragraph trade-off analysis is being finalised by the review team.
IC composite score · 6 weighted factors
How we score Injective
Editorial review pending. Our review team has not yet finalised all six factor scores for Injective. The methodology is documented at /methodology; per our editorial standards we do not publish a composite based on partial factor data.
Letter grade and grade-meaning explanation will appear once the editorial review is finalised.
Pros & cons · the honest version
What works, what doesn't
Pros
- Editorial pros pending — to be published with the next quarterly review.
Cons
- Editorial cons pending — a pros-only review is a brand violation, so this section is omitted (rather than fabricated) until the editor fills it.
Compare · same category
INJ vs. the alternatives
Injective
- Score —
- Mkt cap $2.7B
- 1Y return +18.6%
- TVL —
- Stake yield 10.2% APY
- Spot ETF None
Bitcoin A
- Score 4.9
- Mkt cap $1.94T
- 1Y return +38.4%
- TVL —
- Stake yield —
- Spot ETF Live
Ethereum A
- Score 4.8
- Mkt cap $436B
- 1Y return +24.2%
- TVL $78B
- Stake yield 3.4% APY
- Spot ETF Live
Solana C
- Score 3.9
- Mkt cap $101B
- 1Y return +82.1%
- TVL $14.2B
- Stake yield 6.5% APY
- Spot ETF None